Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.
| 1.25 | |
| 1.25 | |
| - | |
| 1.29 | |
| 1.2185 | |
| 0.622-2.5 | |
| 22 485 K | |
| 17 988 K | |
| 0 | |
| -0.46 | |
| 2.25 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
In this piece, we will take a look at the top ten stock picks of Ken Griffin and his hedge fund Citadel Investment Group. If you want to skip our introduction to the billionaire hedge fund boss and hi...
-- Top-line Data for Pivotal REASSURE Trial Expected in Early Q1 2024 – --Resubmission of NDA for uUTI Expected in Q2 2024-- DUBLIN, Ireland and CHICAGO, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Iteru...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
